Screener
Sutro Biopharma STRO Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Research and development | 36,553 | 51,597 |
| General and administrative | 7,584 | 13,273 |
| Restructuring and related costs | 42 | 21,043 |
| Total operating expenses | 44,179 | 85,913 |
| Loss from operations | (29,656) | (68,514) |
| Interest income | 1,635 | 3,189 |
| Non-cash interest expense related to the sale of future royalties | (9,467) | (9,344) |
| Interest and other income (expense), net | (1,011) | (1,292) |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's other operating expenses?
- Sutro Biopharma (STRO) reported other operating expenses of $44.18M in Q1 2026.
- How has Sutro Biopharma's other operating expenses changed year-over-year?
- Sutro Biopharma's other operating expenses decreased by 48.6% year-over-year, from $85.91M to $44.18M.
- What is the long-term trend for Sutro Biopharma's other operating expenses?
- Over 4 years (2021 to 2025), Sutro Biopharma's other operating expenses has grown at a 12.9% compound annual growth rate (CAGR), from $160.4M to $260.85M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Sutro Biopharma's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude